TickerTalks
Browse all tickers →
TickerTalks›$AMGN
AMAMGN

Amgen Inc.

$AMGN·$222B·Drug Manufacturers - General·Healthcare
$429.88-0.6%YTD+18.6%1Y+49.8%
Mentions · last 7 days
2026-08-22: 11 posts2026-08-23: 13 posts197-1%
Price updated 8h ago·X counts updated 8d ago
AMAMGN
$AMGNAmgen Inc.
$429.88-0.59%197 posts-1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AMGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-09-01

The move is getting stronger, with heavier trading behind it.

Amgen just printed a Tezspire Phase 3 win and Repatha mortality data — the stock's at all-time highs on real pipeline execution.

Amgen is a global biotech giant with a broad immunology, cardiovascular, oncology, and rare-disease portfolio. Recent Phase 3 wins (Tezspire in eosinophilic esophagitis) and a positive Repatha mortality readout have driven the stock to all-time highs with mechanics catching up.

  • Revenue growth is real: last four quarters printed 6-12% YoY at operating margin 26-40% — a durable mid-single-digit growth profile with strong operating leverage.
  • The last four EPS prints beat consensus by 6-15% each — a durable beat streak that has FY27 EPS estimates drifting up to $23.4 (from $22.4 FY26) and validates the pipeline execution narrative.
  • Position sits at the 92nd percentile of the 52-week range on volume 66% of normal — near all-time highs with the accumulation still steady, not chasing.
  • The Repatha mortality data (20% reduction in death risk) is genuinely significant — it strengthens the cardiovascular franchise pricing and durability. Tezspire hitting primary in EoE opens a new indication. Insider selling has been small ($1.3M Khosla) — nothing that changes the picture.

The path forward is decided by the Nov 3 Q3 print — Repatha revenue trajectory post-mortality data, MariTide obesity Phase 2 readouts, and any color on Lp(a) cardiovascular drug positioning. A beat with continued pipeline validation continues the acceleration; a MariTide GIP-antagonism concern materializing or a competitor Repatha challenge invalidates the setup.

Agrees with X sentimentAligned with the bullish thread — Tezspire Phase 3 win in eosinophilic esophagitis (co-primary + all key secondary endpoints), the emerging Lp(a) race positioning, and fresh S&P 500 all-time highs all check out. The MariTide GIP-antagonism concern is a legitimate longer-term question but the base is real.

What to watch: The Nov 3 Q3 print — Repatha revenue trajectory post-mortality data, MariTide obesity Phase 2 readouts, and Lp(a) cardiovascular positioning color. A MariTide GIP-antagonism concern or a Repatha competitor challenge invalidates the acceleration; a beat plus continued pipeline validation continues the run.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment11 posts analyzed · as of 2026-08-31

Chatter is thin but skewed bullish, driven almost entirely by Amgen's positive Phase 3 readout for Tezspire in eosinophilic esophagitis, which met both co-primary and all key secondary endpoints. Several posts flag Amgen making fresh S&P 500 all-time highs and its position in the emerging Lp(a) cardiovascular drug race. Deeper commentary muses on oncology M&A candidates and raises lingering questions about GIP antagonism in the MariTide obesity program.

Read the AI verdict + X sentiment for $AMGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops biologics for oncology, cardiovascular, bone health, and inflammation with a growing biosimilar portfolio and obesity pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AMGN.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $AMGN

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+45.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
24.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
31.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
89.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
71.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
6.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$6.29$5.62+11.9%
Q1 2026Apr 30, 2026$5.15$4.77+8.0%
Q4 2025Feb 3, 2026$5.29$4.73+11.8%
Q3 2025Nov 4, 2025$5.64$5.02+12.4%
Next earningsTue, Nov 3·consensus EPS $5.79

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.6B+5.8%68.2%30.9%$3.37$1.5B
Q4 FY25$9.9B+8.9%81.9%39.8%$2.47$961.0M
Q3 FY25$9.6B+12.4%67.8%26.4%$5.98$4.2B
Q2 FY25$9.2B+9.3%67.2%28.8%$2.66$1.9B

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$37.7B$37.3B – $38.2B$22.36$22.01 – $22.6524
FY27$38.7B$37.7B – $40.0B$23.42$22.10 – $24.2522
FY28$39.8B$36.7B – $44.5B$24.42$19.68 – $26.8625
FY29$41.1B$39.7B – $43.5B$25.85$24.71 – $27.8212
FY30$42.7B$41.2B – $45.2B$27.48$26.27 – $29.5812

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+21.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 538.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.415-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 13Rachna KhoslaSVP, Business Development1.3K sh$521KSellAug 11Rachna KhoslaSVP, Business Development2.0K sh$825KSellAug 6Nancy A. GrygielSVP & CCO1.0K sh$402KSellAug 6Derek MillerSVP, Human Resources1.8K sh$733K
+ 56 other (29 awards · 24 inkinds · 3 exempts) in window

See when $AMGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial eventJul 318-K — Item 1.05
AI summary

Amgen Inc. disclosed a material cybersecurity incident (Item 1.05) in which unauthorized actors exfiltrated data — including proprietary company data and patient protected health information — from cloud environments hosted by third-party providers. Amgen determined the incident is material as of July 29, 2026, activated its incident response plan, and engaged forensic experts. No impact to products, manufacturing, or financial reporting has been identified; the investigation is ongoing and regulatory/legal notification requirements are being assessed. Amgen believes the financial impact is not reasonably likely to be material, but IP and patient data exposure at this scale is a reputational and regulatory risk.

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

Amgen Inc. (AMGN) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor, shareholder proposals. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KOfficer or director changeMay 198-K — Item 5.02: Officer or director change
AI summary

Amgen Inc. (AMGN) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Executive Officer. Individuals named in the filing include Amgen Inc, Its Charter. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 228-K — Item 5.02: Officer or director change
AI summary

AMGN disclosed a personnel change (8-K Item 5.02, dated 2026-04-22). An executive departure and a new appointment are both reported. President and Chief Technology Officer. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 14 other (4 proxys · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKEprnewswire.com·1d agoOne Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%investors.com·1d agoAmgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com·3d agoBlue Edge Capital LLC Purchases New Position in Amgen Inc. $AMGNdefenseworld.net·4d agoAZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Studyzacks.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$NVO$JNJ$GILD$ABBV$AZN
Voices on X · top 12 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport